LoPriore Vincent S's Form 4 filing
Hepion Pharmaceuticals, Inc. (HEPA) · filed Apr 27, 2026
- Accession no.
- 0001493152-26-019029
- Filed
- Apr 27, 2026, 6:24 AM ET
- Trade date
- Apr 21, 2026
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $250.0K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LoPriore Vincent SCIK 0001633927 | Director, Officer (Executive Chairman), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +5,000,000 | $0.04 | +$200,000 | 5,000,000 | Indirect | |
| Apr 21, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +1,250,000 | $0.04 | +$50,000 | 6,250,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.